Neoplasms by Site Recruiting Phase 2 Trials for Lutetium Lu-177 vipivotide tetraxetan (DB16778)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0030096 (Neoplasms by Site) | Recruiting | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | Treatment |